Great Lakes Clinical Trials Sponsors Dementia-Friendly Boat Cruise


On Tuesday, Sept. 24, those with memory impairment and their care partners or family members throughout the Chicago area will be welcomed aboard the glass-topped Odyssey Chicago boat for a dementia-friendly cruise on the Chicago River.

For the second straight year, Great Lakes Clinical Trials is proud to announce this a sponsor of this year’s event., along with the the Alzheimer’s Disease Cooperative Study’s T2 Protect AD Trial .

In addition to helping make this event as low-cost as possible for attendees (their contribution directly covers the full ticket value and transportation for the families and care partners), they’re giving attendees newly-made quilts from their Alzheimer’s Study Quilt Project.

“We are so pleased to be joining the T2 Study in supporting this important event,” commented Steve Satek, President of Great Lakes Clinical Trials. “Guests are able to take in the sites of Chicago in a safe, friendly environment from a unique perspective. We recognize that events like this can enhance quality of life for both patients and their caregivers, so we are continuing to be strong backers of this cruise.”


The cruise was inspired by the work of Kathy Shoaf, a geriatric neurology nurse and owner of Elite Cruises and Vacations Travel, a travel service catering to the needs of people with cognitive impairment, their caregivers, and family members. Boat staff are specially trained by Kathy to accommodate all guests and approach them with a sense of understanding for their unique need

This event is open to the public and is made it possible thanks to the generosity of marquis sponsors: Artis Senior Living of Lakeview, Pathway to Living/Waterton, Great Lakes Clinical Trials, and Peck Ritchey, LLC.

The event is currently sold out, however plans are already in the works for the 2020 cruise.

About the T2 Study

T2 Protect AD is a clinical trial testing the investigational drug troriluzole in people with mild to moderate Alzheimer’s disease (AD). T2 Protect AD is taking place at dozens of sites across the United States. Great Lakes Clinical Trials is one of only 2 centers in the Chicago region that is conducting this trial.

The study is designed to determine if troriluzole can protect against, slow down, and potentially improve memory and thinking problems that increase as Alzheimer’s disease progresses.

If you are interested in learning more about this study and potentially joining the cause, you can visit our website by clicking this link: T2 Protect Study.

About Great Lakes Clinical Trials

Great Lakes Clinical Trials is one of the nation’s leading Alzheimer’s Disease Research Centers. Under the direction of the company’s Medical Director Dr. Jeffrey Ross and the company’s founder, Steve Satek, Great Lakes Clinical Trials has conducted more than 25 Alzheimer’s disease research trials in the past 5 years and screened more than 2,500 patients for those studies.

All services at Great Lakes Clinical Trials are provided at no cost and no insurance is required. Free transportation is provided to and from our clinic for study participants.

If you are interested in learning more about clinical studies at Great Lakes Clinical Trials, you can visit our website by clicking this link:: Clinical Trials